Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic therapy
- REFERENCES
1. Kopp SL, Vandermeulen E, McBane RD, Perlas A, Leffert L, Horlocker T. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine. Evidence-Based Guidelines (fifth edition). Regional Anesthesia & Pain medicine. 2025 http://orcid.org/0000-0003-2997-5445
2. Gogarten W, Vandermeulen E, Van Aken H , et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010;27:999–1015. doi:10.1097/EJA.0b013e32833f6f6f
3. Horlocker TT, Wedel DJ, Rowlingson JC , et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010;35:64–101. doi:10.1097/aap.0b013e3181c15c70
4. Horlocker TT, Vandermeuelen E, Kopp SL , et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med 2018;43:263–309. doi:10.1097/AAP.0000000000000763
5. Kietaibl S, Ferrandis R, Godier A , et al. Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines. Eur J Anaesthesiol 2022;39:100–32. doi:10.1097/EJA.0000000000001600
6. Narouze S, Benzon HT, Provenzano D, et al. (ASRA/ESRA consensus). Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition). Guidelines From the American Society of Regional Anesthesia (ASRA) and Pain Medicine, the European Society of Regional Anaesthesia (ESRA) and Pain Therapy, the American Academy of Pain Medicine (AAPM), the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2018;43(3):225-262.
7. Benzon HT, Nelson AM, Patel AG , et al. Literature review of spinal hematoma case reports: causes and outcomes in pediatric, obstetric, neuraxial and pain medicine cases. Reg Anesth Pain Med 2024. doi:10.1136/rapm-2023-105161
8. Geerts WH, Bergqvist D, Pineo GF , et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S–453S. doi:10.1378/chest.08-0656
9. Barbar S, Noventa F, Rossetto V , et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010;8:2450–7. doi:10.1111/j.1538-7836.2010.04044.x
10. Spyropoulos AC, Anderson FA, FitzGerald G , et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011;140:706–14. doi:10.1378/chest.10-1944
11. Bahl V, Hu HM, Henke PK , et al. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 2010;251:344–50. doi:10.1097/SLA.0b013e3181b7fca6
12. Douketis JD, Spyropoulos AC, Duncan J , et al . Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med 2019;179:1469–78. doi:10.1001/jamainternmed.2019.2431
13. Steffel J, Collins R, Antz M , et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021;23:1612–76. doi:10.1093/europace/euab065
14. Afshari A, Ageno W, Ahmed A , et al. European Guidelines on perioperative venous thromboembolism prophylaxis: Executive summary. Eur J Anaesthesiol 2018;35:77–83. doi:10.1097/EJA.0000000000000729
15. Samama CM, Afshari A, Force EVGT. European guidelines on perioperative venous thromboembolism prophylaxis. Eur J Anaesthesiol 2018;35:73–6. doi:10.1097/EJA.000000000000070
16. Rosencher N, Bonnet MP, Sessler DI. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 2007;62:1154–60. doi:10.1111/j.1365-2044.2007.05195.x
17. Douxfils J, Ageno W, Samama C-M , et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018;16:209–19. doi:10.1111/jth.13912
18. Godier A, Dincq A-S, Martin A-C , et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J 2017;38:2431–9. doi:10.1093/eurheartj/ehx403
19. Dunois C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). Biomedicines 2021;9:445. doi:10.3390/biomedicines9050445
20. Boissier E, Senage T, Babuty A , et al. Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels. Anesth Analg 2021;132:707–16. doi:10.1213/ANE.0000000000005114
21. Faraoni D, Levy JH, Albaladejo P , et al. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care 2015;19:203. doi:10.1186/s13054-015-0930-9
22. Douketis JD, Syed S, Schulman S. Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines. Reg Anesth Pain Med 2016;41:127–9. doi:10.1097/AAP.0000000000000360
23. Andexxa: full prescribing information. Available: https://www.andexxa.com/prescribing-information.html [Accessed 18 Aug 2022].
24. Lu G, DeGuzman FR, Hollenbach SJ , et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19:446–51. doi:10.1038/nm.3102
25. Praxbind full prescribing information. 2015. Available: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Praxbind/Praxbind.pdf [Accessed 18 Aug 2022].
26. Zada I, Wang S, Akerman M , et al. Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants. J Intensive Care Med 2021;36:58–62. doi:10.1177/0885066619882909
27. Stafford-Smith M. Impaired haemostasis and regional anaesthesia. Can J Anaesth 1996;43:R129–41. doi:10.1007/BF03011675
28. Vandermeulen E, Singelyn F, Vercauteren M , et al. Belgian guidelines concerning central neural blockade in patients with drug-induced alteration of coagulation: an update. Acta Anaesthesiol Belg 2005;56:139–46.
29. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012;32:546–58. doi:10.1002/j.1875-9114.2011.01049.x
30. Cuker A, Arepally GM, Chong BH , et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018;2:3360–92. doi:10.1182/bloodadvances.2018024489
31. Lubenow N, Kempf R, Eichner A , et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002;122:37–42. doi:10.1378/chest.122.1.37
32. Garcia DA, Baglin TP, Weitz JI , et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e24S–e43S. doi:10.1378/chest.11-2291
33. Moen V, Dahlgren N, Irestedt L. Severe Neurological Complications after Central Neuraxial Blockades in Sweden 19901999. Anesthesiology 2004;101:950–9.doi:10.1097/00000542-200410000-00021
34. Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994;79:1165–77. doi:10.1213/00000539-199412000-00024
35. Fox KAA, Mehta SR, Peters R , et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome. Circulation 2004;110:1202–8. doi:10.1161/01.CIR.0000140675.85342.1B
36. Rao TLK, El-Etr AA. Anticoagulation Following Placement of Epidural and Subarachnoid Catheters. Anesthesiology 1981;55:618–20. doi:10.1097/00000542-198155060-00002
37. Wulf H. Epidural anaesthesia and spinal haematoma. Can J Anaesth 1996;43:1260–71. doi:10.1007/BF03013437
38. Rosen DA, Hawkinberry DW, Rosen KR , et al. An Epidural Hematoma in an Adolescent Patient After Cardiac Surgery. Anesthesia Analgesia 2004;98:966–9. doi:10.1213/01.ANE.0000103267.37895.5B
39. Ho AM, Chung DC, Joynt GM. Neuraxial blockade and hematoma in cardiac surgery: estimating the risk of a rare adverse event that has not (yet) occurred. Chest 2000;117:551–5. doi:10.1378/chest.117.2.551
40. Schulman S, Beyth RJ, Kearon C , et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:257S–298S. doi:10.1378/chest.08-0674
41. Pace M, Koury K, Gulur P. Epidurals in patients receiving thromboprophylaxis with unfractionated heparin three times a day: the value of activated partial thromboplastin time testing. Anesth Analg 2014;119:1215–8. doi:10.1213/ANE.0000000000000437
42. Davis JJ, Bankhead BR, Eckman EJ , et al. Three-times-daily subcutaneous unfractionated heparin and neuraxial anesthesia: a retrospective review of 928 cases. Reg Anesth Pain Med 2012;37:623–6. doi:10.1097/AAP.0b013e31826a8d10
43. Su J, Soliz JM, Popat KU , et al. Epidural Analgesia and Subcutaneous Heparin 3 Times Daily in Cancer Patients With Acute Postoperative Pain. Anesth Analg 2018;127:e57–9. doi:10.1213/ANE.0000000000003603
44. VanderWielen B, Rubenstein L, Shnider M , et al. Recognition of a Thoracic Epidural Hematoma in the Setting of Transient Paralysis. A A Case Rep 2017;8:294–6. doi:10.1213/XAA.0000000000000492
45. Greaves JD. Serious spinal cord injury due to haematomyelia caused by spinal anaesthesia in a patient treated with low-dose heparin. Anaesthesia 1997;52:150–4. doi:10.1111/j.1365-2044.1997.63-az0065.x
46. Cosmi B, Hirsh J. Low molecular weight heparins. Curr Opin Cardiol 1994;9:612–8. doi:10.1097/00001573-199409000-00017
47. Shaikh SA, Regal RE. Dosing of Enoxaparin in Renal Impairment. P T 2017;42:245–9.
48. Henshaw DS, Turner JD, Forest DJ , et al. Residual Enoxaparin Activity, Anti-Xa Levels, and Concerns About the American Society of Regional Anesthesia and Pain Medicine Anticoagulation Guidelines. Reg Anesth Pain Med 2017;42:432–6. doi:10.1097/AAP.0000000000000617
49. Henshaw DS, Edwards CJ, Dobson SW , et al. Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: a prospective observational trial. Reg Anesth Pain Med 2024;49:94–101. doi:10.1136/rapm-2023-104571
50. Sharma V, Terrell L, Karlapalem C , et al. 1020: therapeutic enoxaparin in morbidly obese patients: single-center experience. Crit Care Med 2023;51:504. doi:10.1097/01.ccm.0000909808.50243.3e
51. Urmey WF, Rowlingson J. Do antiplatelet agents contribute to the development of perioperative spinal hematoma? Reg Anesth Pain Med 1998;23:146–51. doi:10.1016/S1098-7339(98)90140-7
52. Horlocker TT, Bajwa ZH, Ashraf Z , et al. Risk assessment of hemorrhagic complications associated with nonsteroidal antiinflammatory medications in ambulatory pain clinic patients undergoing epidural steroid injection. Anesth Analg 2002;95:1691–7. doi:10.1097/00000539-200212000-00041
53. Giberson CE, Barbosa J, Brooks ES , et al. Epidural hematomas after removal of percutaneous spinal cord stimulator trial leads: two case reports. Reg Anesth Pain Med 2014;39:73–7. doi:10.1097/AAP.0000000000000026
54. Amezcua JL, O’Grady J, Salmon JA , et al. Prolonged paradoxical effect of aspirin on platelet behaviour and bleeding time in man. Thromb Res 1979;16:69–79. doi:10.1016/0049-3848(79)90270-6
55. Eikelboom JW, Hirsh J, Spencer FA , et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e89S–e119S. doi:10.1378/chest.11-2293
56. Cronberg S, Wallmark E, Söderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984;33:155–9. doi:10.1111/j.1600-0609.1984.tb02390.x
57. Leese PT, Hubbard RC, Karim A , et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40:124–32. doi:10.1177/00912700022008766
58 Douketis JD, Spyropoulos AC, Murad MH , et al. Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest 2022;162:1127–39. doi:10.1016/j.chest.2022.08.004
59. Plavix prescribing information n.d. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020839s048lbl.pdf
60. Prasurgel. n.d. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022307s003lbl.pdf
61. Price MJ, Walder JS, Baker BA , et al. Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease. J Am Coll Cardiol 2012;59:2338–43. doi:10.1016/j.jacc.2012.02.042
62. Gurbel PA, Bliden KP, Butler K , et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. Circulation 2009;120:2577–85. doi:10.1161/CIRCULATIONAHA.109.912550
63. Hansson EC, Malm CJ, Hesse C , et al. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery. Eur J Cardiothorac Surg 2017;51:633–7. doi:10.1093/ejcts/ezw373
64. Full prescribing information. Available: http://www.azpicentral.com/brilinta/brilinta.pdf#page=1 [Accessed 15 Feb 2023].
65. Tummala R, Rai MP. Glycoprotein IIb/IIIa inhibitors. StatPearls, 2023.
66. Kaneda T, Urimoto G, Suzuki T. Spinal epidural hematoma following epidural catheter removal during antiplatelet therapy with cilostazol. J Anesth 2008;22:290–3. doi:10.1007/s00540-008-0623-5
67. Akers WS, Oh JJ, Oestreich JH , et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010;50:27–35. doi:10.1177/0091270009344986
68. Carswell JL, Beard KA, Chevrette MM , et al. Tracking trends in secondary stroke prevention strategies. Ann Pharmacother 2004;38:215–9. doi:10.1345/aph.1D190
69. Greinacher A, Eichler P, Lubenow N , et al. Drug-induced and drug-dependent immune thrombocytopenias. Rev Clin Exp Hematol 2001;5:166–200; . doi:10.1046/j.1468-0734.2001.00041.x
70. Eriksson BI, Wille-Jørgensen P, Kälebo P , et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329–35. doi:10.1056/NEJM199711063371901
71. Turpie AG, Gallus AS, Hoek JA , et al. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344:619–25. doi:10.1056/NEJM200103013440901
72. Landow L. A synthetic pentasaccharide for the prevention of deep-vein thrombosis. N Engl J Med 2001;345:291–2. doi:10.1056/NEJM200107263450412
73. Singelyn FJ, Verheyen CCPM, Piovella F , et al. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg 2007;105:1540–7, . doi:10.1213/01.ane.0000287677.95626.60
74. Bauersachs RM. Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. J Cardiovasc Pharmacol Ther 2023;28:10742484221145010. doi:10.1177/10742484221145010
75. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill, 2006.
76. Chan K-C, Wu D-J, Ueng K-C , et al. Spinal epidural hematoma following tissue plasminogen activator and heparinization for acute myocardial infarction. Jpn Heart J 2002;43:417–21. doi:10.1536/jhj.43.417
77. Ozgocmen S, Yoldas T, Kocakoc E , et al. Spinal epidural hematoma associated with streptokinase treatment for myocardial infarction. Spinal Cord 2004;42:374–7. doi:10.1038/sj.sc.3101604
78. Song KJ, Lee KB. The poor outcome of the delayed diagnosis of acute spontaneous spinal epidural hematoma: two cases report. J Korean Med Sci 2005;20:331–4. doi:10.3346/jkms.2005.20.2.331
79. Gupta K, Sharma R, Agrawal N , et al. Spinal epidural hematoma - A rare and debilitating complication of thrombolytic therapy. J Cardiovasc Dis Res 2013;4:236–8. doi:10.1016/j.jcdr.2014.01.005
80. Hirsh J, Bauer KA, Donati MB , et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:141S–159S. doi:10.1378/chest.08-0689
81. Toyonaga M, Hagiwara N, Irie F , et al. Acute cervical spinal epidural hematoma during antithrombotic therapy: dual warnings against antithrombotic therapy. Rinsho Shinkeigaku 2003;43:287–90.
82. Ansell J, Hirsh J, Hylek E , et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S–198S. doi:10.1378/chest.08-0670
83. Warfarin dosing. Available: www.WarfarinDosing.org [Accessed 1 May 2023].
84. Parvizi J, Viscusi ER, Frank HG , et al. Can Epidural Anesthesia and Warfarin be Coadministered? Clin Orthop Relat Res 2007;456:133–7. doi:10.1097/01.blo.0000246548.25811.2d
85. Benzon HT, Asher Y, Kendall MC , et al. Clotting-Factor Concentrations 5 Days After Discontinuation of Warfarin. Reg Anesth Pain Med 2018;43:616–20. doi:10.1097/AAP.0000000000000782
86. Liu SS, Buvanendran A, Viscusi ER , et al. Uncomplicated removal of epidural catheters in 4365 patients with international normalized ratio greater than 1.4 during initiation of warfarin therapy. Reg Anesth Pain Med 2011;36:231–5. doi:10.1097/AAP.0b013e31820d4376
87. Benzon HT, Avram MJ, Benzon HA , et al. Factor VII levels and international normalized ratios in the early phase of warfarin therapy. Anesthesiology 2010;112:298–304. doi:10.1097/ALN.0b013e3181ca6cfc
88. Woo CH, Patel N, Conell C , et al. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg 2014;81:110-5. doi:10.1016/j.wneu.2012.12.002
89. Lee A, Chui PT, Aun CST , et al. Incidence and risk of adverse perioperative events among surgical patients taking traditional Chinese herbal medicines. Anesthesiology 2006;105:454–61. doi:10.1097/00000542-200609000-00007
90. Moss J, Yuan CS. Herbal medicines and perioperative care. Anesthesiology 2006;105:441–2. doi:10.1097/00000542-200609000-00002
91. Bateman BT, Mhyre JM, Ehrenfeld J, et al. The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the Multicenter Perioperative Outcomes Group Research Consortium. Anesth Analg 2013;116:1380–5
92. Paech MJ, Godkin R, Webster S. Complications of obstetric epidural analgesia and anaesthesia: a prospective analysis of 10,995 cases. Int J Obstet Anesth1998;7:5–11
93. Leffert LR,Dubois HM, Butwick AJ, et al. Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low-Molecular-Weight Heparin: A Systematic Review of Spinal Epidural Hematoma. Anesth Analg 2017;125:223–31. doi:10.1213/ANE.0000000000002173
94. Pujic B, Holo- Djilvesi N, Djilvesi D, et al. Epidural hematoma following low molecular
weight heparin prophylaxis and spinal anesthesia for cesarean delivery. Int J Obstet Anesth 2019;37:118–21
95. Pöpping DM, Elia N, Marret E , et al. Protective effects of epidural analgesia on pulmonary complications after abdominal and thoracic surgery: a meta-analysis. Arch Surg 2008;143:990–9. doi:10.1001/archsurg.143.10.990
96. Leffert L, Butwick A, Carvalho B , et al. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants. Anesth Analg 2018;126:928–44. doi:10.1213/ANE.0000000000002530
97. The American College of Obstetricians and Gynecologists. Inherited Thrombophilias in Pregnancy. Pract Bull 2018;197.
98. Parvaiz MA, Korwar V, McArthur D , et al. Large retroperitoneal haematoma: an unexpected complication of ilioinguinal nerve block for inguinal hernia repair. Anaesthesia 2012;67:80–1. doi:10.1111/j.1365-2044.2011.06971.x
99. Idestrup C, Sawhney M, Nix C , et al. The incidence of hematoma formation in patients with continuous femoral catheters following total knee arthroplasty while receiving rivaroxaban as thromboprophylaxis: an observational study. Reg Anesth Pain Med 2014;39:414–7. doi:10.1097/AAP.0000000000000127
100. Tsui BCH, Kirkham K, Kwofie MK , et al. Practice advisory on the bleeding risks for peripheral nerve and interfascial plane blockade: evidence review and expert consensus. Can J Anaesth 2019;66:1356–84. doi:10.1007/s12630-019-01466-w
101. Douketis JD, Spyropoulos AC, Murad MH , et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest 2022;162:e207–43. doi:10.1016/j.chest.2022.07.025
102. BMS. Apixaban full prescribing information.
Available: http://packageinserts.bms.com/pi/pi_eliquis.pdf [Accessed 13 Mar 2024].
103. Savaysa: full prescribing information.
Available: http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true [Accessed 18 Aug 2022].
104. Rivaroxaban: full prescribing information.
Available: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf [Accessed 18 Aug 2022].
105. Pradaxa: full prescribing infomation.
Available: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf [Accessed 18 Aug 2022].